Evidence map›Paper›PMID 34501095›Full record

ArticleMaterials (Basel, Switzerland)2021

In Vitro Investigation on Degradable Mg-Based Biomaterial under the Impact of the Serum Glycoprotein Fetuin.

Heike Helmholz, Blessing Adejube, Bérengère Luthringer-Feyerabend, Regine Willumeit-Römer

Open access · goldAbstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. MWCNTs-TiOMaterials (Basel, Switzerland) · 2023
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Heike HelmholzHelmholtz Zentrum Hereon, Institute of Metallic Biomaterials, Max Planck St., 21502 Geesthacht, Germany.ORCID 0000-0001-6457-3607
Blessing AdejubeFaculty of Engineering, Cristian Albrecht University Kiel, Kaiserstraße 2, 24143 Kiel, Germany.
Bérengère Luthringer-FeyerabendHelmholtz Zentrum Hereon, Institute of Metallic Biomaterials, Max Planck St., 21502 Geesthacht, Germany.
Regine Willumeit-RömerHelmholtz Zentrum Hereon, Institute of Metallic Biomaterials, Max Planck St., 21502 Geesthacht, Germany.
Christian-Albrechts-Universität zu Kiel · DEHelmholtz-Zentrum Hereon · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biomedical applications of magnesium (Mg) and its alloys are generally dependent on their degradation behavior in vivo. Despite its attractive properties, which make Mg suitable for orthopedic applications, the in vivo material-tissue (bone, blood, and lymph tissues) interaction is not yet fully understood. To investigate the influence of major serum proteins on the degradation, this study focused on fetuin, which is one of the major non-collagenous plasma proteins and which is essential for biomineralization. This study used a physiological setup to investigate the influence of fetuin on the degradation behavior of pure Mg in the presence of calcium (Ca). Extruded pure Mg samples were immersed under cell culture conditions in Hank's balanced salt solution (HBSS) under defined Ca regimes. The results showed a significant decrease in the degradation rate (DR) when both fetuin and Ca were present in an immersion medium as compared to media where they were not simultaneously present. A possible reason for this behavior was the forming of a dense, protein-degradation products protection barrier at the material surface. Furthermore, the limitation of freely available Ca might be a reason for a decreased degradation. The cultivation of primary osteoblasts (pOB) was possible at the fetuin-coated Mg-surface without additional serum supplementation.

Indexed as

AHSGbiomineralizationimplantmagnesiumosteoblast

Identifiers

PMID34501095
PMCPMC8434450
OpenAlexW3198884417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.